Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well trabectedin works in treating young patients with
recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in
chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they
stop growing or die.